Characteristics | Parameters |
---|---|
Age (∑ = 267) | |
  ≤ 60 | 161 (60.3%) |
  > 60 | 106 (39.7%) |
Gender (∑ = 291) | |
 Male | 143 (49.1%) |
 Female | 148 (50.8%) |
Symptoms (∑ = 300) | |
 Bleeding or anemia | 128 (42.7%) |
 Abdominal pain | 56 (18.7%) |
 Abdominal mass | 11 (3.7%) |
 Abdominal discomfort | 11 (3.7%) |
 Anorexia | 6 (2.0%) |
 Othersaa | 36 (12.0%) |
Anatomical location (∑ = 266) | |
 Superior portion | 42 (15.8%) |
 Descending portion | 137 (51.5%) |
 Horizontal portion | 65 (24.4%) |
 Ascending portion | 22 (8.3%) |
Surgical procedure (∑ = 300) | |
 Limited resection* | 199 (66.3%) |
 Pancreaticoduodenectomy | 78 (26.0%) |
 Not available | 13 (4.3%) |
 No surgery | 10 (3.3%) |
Resection margin (∑ = 300) | |
 R0 | 275 (91.7%) |
 R1/2 | 2 (0.7%) |
 Not available/No surgery | 23 (7.7%) |
Tumor size (∑ = 277) | |
  ≤ 2 cm | 34 (12.3%) |
 2–5 cm | 135 (48.7%) |
 5–10 cm | 73 (26.4%) |
  > 10 cm | 35 (12.6%) |
Mitotic index (∑ = 240) | |
  ≤ 5 | 181 (75.4%) |
  > 5 | 59 (24.6%) |
Morphology (∑ = 160) | |
 Spindle | 148 (92.5%) |
 Epithelioid | 1 (0.6%) |
 Mixed | 11 (6.9%) |
Immunohistochemistry | |
 CD117 (∑ = 288) | 284 (98.6%) |
 DOG-1 (∑ = 41) | 40 (97.6%) |
 CD34 (∑ = 167) | 126 (75.4%) |
Genomic mutation (∑ = 41) | |
 KIT | 31 (75.6%) |
 PDGFRA | 1 (2.4%) |
 KIT and PDGFRA | 5 (12.2%) |
 Wild type | 4 (9.8%) |
NIH risk category (∑ = 258) | |
 Very low | 25 (9.7%) |
 Low | 104 (40.3%) |
 Intermediate | 2 (0.8%) |
 High | 127 (49.2%) |
Neoadjuvant therapy (∑ = 300) | |
 No | 287 (95.7%) |
 Yes | 13 (4.3%) |
Adjuvant therapy (∑ = 300) | |
 No | 263 (87.7%) |
 Yes | 37 (12.3%) |
Follow-up (∑ = 202, month) | |
 Mean ± SD | 39.3 ± 39.4 |
 Median (range) | 25.0 (13.0, 58.5) |
Survival rate (∑ = 202) | |
 1−/3−/5−/10-year DFS | 94.4%/75.2%/64.4%/46.5% |
 1−/3−/5−/10-year DSS | 99.5%/93.4%/80.9%/54.5% |